Matrix Capital Management Company, LP
In its 13F for Q4 2025 (holdings as of December 31, 2025, filed February 13, 2026), Matrix Capital Management Company, LP reported 2 stock positions worth $57.6 million. Its top holding was Aura Biosciences (AURA) at 65.5% of the portfolio, followed by Maze Therapeutics (MAZE, 34.5%). Compared with Q3 2025, it sold out of 1 and reduced 1. The biggest sale was an exit from Zentalis Pharmaceuticals (ZNTL).
- Most Recent 13F
- Q2 2026
- Location
- Portsmouth, NH
- CIK
- 0001410830
- Portfolio Value
- $57.6M (Q4 2025)
- SEC Filing
- 0001172661-26-000728 ↗ filed Feb 13, 2026
Holdings Value
Holdings 2 stocks · $57.6M
Portfolio Sells Q3 2025 → Q4 2025
Portfolio Buys Q3 2025 → Q4 2025
| None this quarter. | |||
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 0 | $0 | |
| Q1 2026 | 1 | $46.3M | AURA |
| Q4 2025 | 2 | $57.6M | AURA, MAZE |
| Q3 2025 | 3 | $106.7M | MAZE, AURA, ZNTL |
| Q2 2025 | 4 | $222.8M | GFS, AURA, MAZE, ZNTL |
| Q1 2025 | 4 | $347.2M | GFS, AURA, MAZE, ZNTL |
| Q4 2024 | 5 | $2.2B | ALTR, GFS, PRM, AURA, ZNTL |
| Q3 2024 | 7 | $2.1B | ALTR, GFS, PRM, AURA, ZNTL |
| Q2 2024 | 23 | $13.1B | NVDA, QCOM, TDG, ALTR, MRVL |
| Q1 2024 | 23 | $10.8B | NVDA, TDG, QCOM, ALTR, MRVL |